1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Mosbah, A.
Marrakchi, N.
Ganzalez, M.J.
Van Rietschoten, J.
Giralt, E.
El Ayeb, M.
Rochat, H.
Sabatier, J.M.
Darbon, H.
Mabrouk, K.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
Lebetin peptides, a new class of potent aggregation inhibitors
10.2210/pdb1q01/pdb
pdb_00001q01
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
3954.437
lebetin 2 isoform alpha
1
nat
polymer
no
no
GDNKPPKKGPPNGCFGHKIDRIGSHSGLGCNKVDDNKG
GDNKPPKKGPPNGCFGHKIDRIGSHSGLGCNKVDDNKG
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Levantine viper
Macrovipera
sample
8709
Macrovipera lebetina
venom
database_2
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2005-05-03
1
1
2008-04-29
1
2
2011-07-13
1
3
2022-03-02
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
N
RCSB
Y
RCSB
2003-07-15
REL
back calculated data agree with experimental NOESY spectrum,structures with acceptable covalent geometry,structures with favorable non-bond energy,structures with the least restraint violations,structures with the lowest energy,target function
50
24
DQF-COSY
2D TOCSY
2D NOESY
DQF-COSY
2D TOCSY
2D NOESY
3
ambient
280
K
3
ambient
283
K
Diana and CNS, distance geometry, simulated annealing
1
fewest violations, lowest energy
90% H2O, 10% D2O
90% H2O, 10% D2O
collection
XwinNMR
processing
XwinNMR
data analysis
XEASY
structure solution
DIANA
refinement
CNS
500
Bruker
DRX
GLY
1
n
1
GLY
1
A
ASP
2
n
2
ASP
2
A
ASN
3
n
3
ASN
3
A
LYS
4
n
4
LYS
4
A
PRO
5
n
5
PRO
5
A
PRO
6
n
6
PRO
6
A
LYS
7
n
7
LYS
7
A
LYS
8
n
8
LYS
8
A
GLY
9
n
9
GLY
9
A
PRO
10
n
10
PRO
10
A
PRO
11
n
11
PRO
11
A
ASN
12
n
12
ASN
12
A
GLY
13
n
13
GLY
13
A
CYS
14
n
14
CYS
14
A
PHE
15
n
15
PHE
15
A
GLY
16
n
16
GLY
16
A
HIS
17
n
17
HIS
17
A
LYS
18
n
18
LYS
18
A
ILE
19
n
19
ILE
19
A
ASP
20
n
20
ASP
20
A
ARG
21
n
21
ARG
21
A
ILE
22
n
22
ILE
22
A
GLY
23
n
23
GLY
23
A
SER
24
n
24
SER
24
A
HIS
25
n
25
HIS
25
A
SER
26
n
26
SER
26
A
GLY
27
n
27
GLY
27
A
LEU
28
n
28
LEU
28
A
GLY
29
n
29
GLY
29
A
CYS
30
n
30
CYS
30
A
ASN
31
n
31
ASN
31
A
LYS
32
n
32
LYS
32
A
VAL
33
n
33
VAL
33
A
ASP
34
n
34
ASP
34
A
ASP
35
n
35
ASP
35
A
ASN
36
n
36
ASN
36
A
LYS
37
n
37
LYS
37
A
GLY
38
n
38
GLY
38
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
ASP
2
68.49
-68.10
1
A
LYS
8
-51.14
178.55
1
A
PRO
11
-69.98
63.34
1
A
ASN
12
61.24
112.90
1
A
CYS
14
-57.65
-164.91
1
A
LYS
18
-90.81
49.30
1
A
ILE
22
54.51
173.83
2
A
LYS
4
-108.40
77.01
2
A
LYS
7
59.70
161.53
2
A
ASN
12
-165.48
-168.29
2
A
CYS
14
60.65
156.67
2
A
LYS
18
74.90
96.18
2
A
ASP
20
58.46
160.82
2
A
ILE
22
54.58
173.61
2
A
ASN
31
-56.57
-178.71
2
A
LYS
32
59.87
73.60
2
A
ASP
34
-105.36
56.42
2
A
ASN
36
66.10
-73.64
2
A
LYS
37
-175.15
-41.78
3
A
ASP
2
-153.90
80.59
3
A
ASN
12
-179.62
-178.48
3
A
PHE
15
-59.07
-178.33
3
A
HIS
17
-56.06
-178.29
3
A
LYS
18
-88.04
48.82
3
A
ASP
20
54.82
105.31
3
A
LEU
28
-47.17
170.67
3
A
ASP
34
-69.94
61.76
3
A
ASN
36
-50.74
97.01
4
A
ASN
3
-162.92
93.07
4
A
LYS
4
-59.13
109.25
4
A
ASN
12
43.41
91.97
4
A
PHE
15
-59.69
171.96
4
A
LYS
18
-90.73
48.68
4
A
SER
24
-59.74
-74.76
4
A
LEU
28
-52.43
-178.45
4
A
CYS
30
-126.33
-53.38
4
A
LYS
32
-60.04
92.84
5
A
PRO
11
-69.84
84.17
5
A
PHE
15
-52.67
-179.03
5
A
LYS
18
-90.90
48.95
5
A
HIS
25
-124.35
-61.67
5
A
LEU
28
-55.25
170.78
5
A
CYS
30
-149.09
-53.75
5
A
ASN
36
65.83
-73.44
6
A
PRO
11
-69.91
84.25
6
A
CYS
14
52.63
177.75
6
A
LYS
18
166.92
99.26
6
A
ASP
20
56.36
162.78
6
A
ILE
22
-42.20
161.02
6
A
LEU
28
-67.35
-174.75
6
A
ASP
34
-112.27
54.13
6
A
ASP
35
63.89
-65.82
7
A
ASP
2
-103.04
-65.77
7
A
ASN
3
-151.98
-46.89
7
A
LYS
7
61.30
111.52
7
A
ASN
12
179.91
158.74
7
A
PHE
15
-47.39
151.67
7
A
HIS
17
-59.04
178.77
7
A
LYS
18
74.82
84.18
7
A
ASP
20
59.50
159.96
7
A
ILE
22
54.67
173.58
7
A
HIS
25
-123.07
-59.08
7
A
CYS
30
-102.05
-74.33
7
A
ASP
35
-67.41
97.57
7
A
LYS
37
59.99
85.69
8
A
ASP
2
60.20
83.27
8
A
ASN
12
178.53
-35.39
8
A
LYS
18
75.57
96.82
8
A
ASP
20
50.32
99.14
8
A
ILE
22
54.60
173.72
8
A
CYS
30
-129.99
-75.30
8
A
ASN
31
-61.36
-179.17
8
A
ASP
35
-92.67
-65.75
8
A
ASN
36
-50.93
104.00
9
A
ASP
2
-175.94
-53.63
9
A
ASN
3
-161.48
93.65
9
A
LYS
4
-59.29
109.58
9
A
LYS
8
-56.50
172.67
9
A
ASN
12
-177.48
116.81
9
A
CYS
14
47.24
-174.25
9
A
LYS
18
77.04
97.33
9
A
ASP
20
46.71
94.62
9
A
ARG
21
-56.30
89.08
9
A
ILE
22
54.34
173.47
9
A
SER
24
-122.44
-82.18
9
A
HIS
25
-120.22
-52.23
9
A
SER
26
-49.46
172.78
9
A
LEU
28
-52.66
170.68
9
A
ASN
31
-56.37
-179.06
9
A
ASP
35
-151.05
-47.21
9
A
LYS
37
60.47
80.29
10
A
ASP
2
63.37
-78.76
10
A
ASN
3
74.55
-54.14
10
A
PRO
11
-69.71
92.18
10
A
ASN
12
176.41
-34.33
10
A
CYS
14
60.26
157.71
10
A
HIS
17
-58.14
172.82
10
A
LYS
18
-91.95
49.34
10
A
ILE
22
54.78
173.70
10
A
CYS
30
-109.02
-71.11
10
A
ASP
34
-141.89
59.81
10
A
ASP
35
-151.69
-45.99
10
A
ASN
36
-50.68
176.01
11
A
LYS
4
-59.51
109.98
11
A
PRO
11
-69.84
83.79
11
A
ASN
12
-165.60
32.61
11
A
HIS
17
-56.57
173.96
11
A
LYS
18
-91.56
49.63
11
A
ILE
22
54.55
174.28
11
A
LEU
28
-60.26
-174.94
11
A
CYS
30
-143.91
-47.21
11
A
ASN
31
-69.21
-179.08
11
A
LYS
32
-60.46
95.49
12
A
ASN
3
-176.64
-55.50
12
A
LYS
7
-150.78
76.69
12
A
ASN
12
59.89
109.18
12
A
CYS
14
-122.65
-95.59
12
A
HIS
17
-56.46
173.13
12
A
SER
24
-167.81
-68.53
12
A
HIS
25
-125.90
-59.16
12
A
LYS
32
-176.16
79.30
12
A
ASP
34
-106.59
56.58
12
A
ASN
36
65.80
-73.58
12
A
LYS
37
-176.16
-59.94
13
A
LYS
4
-59.35
109.63
13
A
ASN
12
60.26
109.61
13
A
CYS
14
60.78
156.70
13
A
PHE
15
-55.27
-179.48
13
A
LYS
18
77.53
98.46
13
A
ASP
20
58.26
161.60
13
A
ILE
22
-41.30
161.91
13
A
LYS
32
-176.78
79.42
13
A
ASN
36
176.39
101.54
13
A
LYS
37
60.59
95.67
14
A
ASP
2
68.49
-68.17
14
A
LYS
8
-51.22
178.70
14
A
ASN
12
61.25
112.97
14
A
CYS
14
-57.88
-164.76
14
A
LYS
18
-92.08
48.96
14
A
ILE
22
54.92
173.76
15
A
ASN
3
-117.83
71.58
15
A
LYS
4
-59.35
109.57
15
A
PRO
11
-69.97
63.59
15
A
CYS
14
-122.46
-95.44
15
A
HIS
17
-59.32
175.53
15
A
LYS
18
-94.25
39.58
15
A
ASP
20
-51.19
109.98
15
A
ILE
22
54.50
174.77
15
A
HIS
25
-100.09
-73.60
15
A
SER
26
55.60
171.61
15
A
ASN
36
66.10
-73.90
16
A
ASP
2
60.64
88.29
16
A
LYS
7
-61.00
91.33
16
A
ASN
12
60.26
84.33
16
A
PHE
15
-53.17
-178.75
16
A
LYS
18
-91.04
48.63
16
A
ILE
22
54.68
173.96
16
A
LEU
28
-56.07
170.58
16
A
CYS
30
-147.89
-57.11
16
A
ASN
31
-58.92
172.36
16
A
LYS
32
56.40
79.23
16
A
ASP
35
-92.36
-72.13
16
A
ASN
36
60.34
158.52
17
A
ASP
2
64.07
-79.14
17
A
CYS
14
51.04
179.22
17
A
HIS
17
-56.56
-179.59
17
A
LYS
18
-88.64
48.23
17
A
ASP
20
46.31
92.23
17
A
ILE
22
54.85
173.93
17
A
SER
24
-66.73
-79.66
17
A
HIS
25
-126.83
-57.40
17
A
SER
26
-57.83
172.69
17
A
LYS
32
-176.48
110.52
17
A
ASP
34
-69.80
62.79
17
A
ASN
36
-49.65
175.53
17
A
LYS
37
-176.53
-41.36
18
A
LYS
8
-59.78
173.53
18
A
PRO
11
-69.31
62.99
18
A
HIS
17
-57.47
-177.75
18
A
LYS
18
-85.35
46.55
18
A
ILE
19
-98.23
-64.18
18
A
ASP
20
42.70
92.74
18
A
ILE
22
54.81
173.53
18
A
SER
24
-56.92
-79.07
18
A
HIS
25
-137.83
-64.11
18
A
SER
26
-49.43
172.67
18
A
CYS
30
-129.68
-66.52
18
A
ASP
35
-145.25
-47.26
18
A
ASN
36
-49.97
158.45
18
A
LYS
37
63.72
-79.43
19
A
ASP
2
68.24
-69.98
19
A
PRO
11
-69.35
77.92
19
A
ASN
12
-177.47
112.93
19
A
CYS
14
-58.50
-164.29
19
A
PHE
15
-49.93
166.29
19
A
HIS
17
-56.52
-178.99
19
A
LYS
18
-92.54
40.19
19
A
ASP
20
-61.46
95.07
19
A
SER
24
-107.20
-79.26
19
A
HIS
25
-139.87
-65.52
19
A
SER
26
-52.33
172.17
19
A
ASN
31
-50.40
175.52
19
A
ASP
34
-99.22
59.98
19
A
ASN
36
-50.76
172.05
20
A
ASP
2
68.10
-69.81
20
A
ASN
3
-118.04
71.42
20
A
LYS
4
-59.21
109.89
20
A
PRO
11
-69.80
84.48
20
A
ASN
12
45.44
-168.74
20
A
PHE
15
-60.01
-179.20
20
A
LYS
18
-97.02
41.12
20
A
ILE
22
54.48
173.73
20
A
SER
24
-118.32
-81.54
20
A
SER
26
-59.90
172.03
20
A
LEU
28
-59.59
178.49
20
A
LYS
32
-172.73
89.50
20
A
ASN
36
65.66
-73.39
21
A
ASP
2
60.63
163.90
21
A
ASN
12
-60.11
88.31
21
A
HIS
17
-59.72
178.90
21
A
LYS
18
-87.79
47.19
21
A
ILE
19
-109.64
-71.05
21
A
ASP
20
40.44
93.52
21
A
ARG
21
-59.57
89.96
21
A
ILE
22
57.00
173.51
21
A
SER
26
-48.56
156.48
21
A
CYS
30
-152.54
-56.88
21
A
ASN
31
-54.85
-178.65
21
A
LYS
32
-56.95
101.36
21
A
ASN
36
-51.20
101.34
22
A
ASN
3
-117.89
71.18
22
A
CYS
14
61.37
157.02
22
A
LYS
18
-95.69
38.58
22
A
ARG
21
-59.05
170.01
22
A
ILE
22
-44.89
164.51
22
A
ASP
34
56.30
75.49
22
A
ASP
35
-151.64
-46.84
23
A
ASP
2
60.45
104.59
23
A
PRO
11
-69.99
92.80
23
A
LYS
18
-90.80
49.17
23
A
ARG
21
-100.21
77.67
23
A
SER
24
-131.48
-68.86
23
A
ASP
34
-91.97
56.45
23
A
LYS
37
60.50
110.82
24
A
ASP
2
-176.42
146.49
24
A
ASN
3
-98.88
31.79
24
A
LYS
4
-59.46
109.82
24
A
ASN
12
-164.89
31.77
24
A
LYS
18
-96.73
38.26
24
A
ARG
21
-58.87
170.88
24
A
ILE
22
-46.27
166.82
24
A
CYS
30
-158.29
-46.54
24
A
ASN
31
-59.99
-179.55
24
A
LYS
32
-59.99
98.36
24
A
ASN
36
-50.65
96.25
Lebetin peptides, a new class of potent aggregation inhibitors
1
N
N
disulf
2.029
A
CYS
14
A
SG
CYS
14
1_555
A
CYS
30
A
SG
CYS
30
1_555
BLOOD CLOTTING
BETA-BULGED HAIRPAIN, BLOOD CLOTTING
Q7LZ09_VIPLE
UNP
1
1
Q7LZ09
GDNKPPKKGPPNGCFGHKIDRIGSHSGLGCNKVDDNKG
1
38
1Q01
1
38
Q7LZ09
A
1
1
38